Chris Griffith and Jeff Ward were invited to attend the 3rd China Pharma IP Summit in Beijing held on October 24-26, 2018.
This event focused on a variety of IP topics pertinent to pharma stakeholders located in Asia, including pharma-related IP policies in China, as well as pharma patent examination, management and litigation in the U.S. and Europe. Chris presented on “Navigating the IP/FDA Exclusivity Waters – Recent Developments Affecting the Journey to 505(b)(1), 505(b)(2), ANDA and Biologics Approval in the US.”
